Filing Flows › Omnicell (OMCL) › Guidance & outlook
Omnicell (OMCL) guidance and outlook
Omnicell (OMCL) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $295M–$301M for Q4 2026; Revenue $1.2B for FY2026. Omnicell's 10-Q filed Nov 4, 2026 makes 26 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q4 2026 | $295M–$301M | new |
| Revenue | FY2026 | $1.2B | lowered |
| Revenue | Q4 2026 | $161M–$164M | new |
| Revenue | FY2026 | $684M–$687M | new |
From the earnings release filed Oct 29, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- • our ability to successfully achieve anticipated growth targets or market adoption;
- • failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers;
- • failing to meet (or significantly exceeding) our publicly announced financial guidance; and
- While these actions have effectively mitigated some of the impact of these costs, there can be no assurance that we will be able to offset future increased costs or other adverse impacts.
- Although we continue to work to mitigate the impact of current or potential tariffs, we may incorrectly anticipate outcomes, forgo or pass up business opportunities, or fail to appropriately adapt or manage our business strategies in response to these changes.
- The Company does not expect any additional refunds potentially collectible in the future for IEEPA tariffs paid through the U.S.
- At this time, we do not currently expect these recent tariff changes to have a material impact on our business, operating results, cash flow, or financial condition.
- In addition, dependent upon counterparty or credit risk, which is evaluated at the time of contract signing, for a given multi-year subscription contract we may reduce the value of the contractual commitment booked at a given time.
- We define ARR at a measurement date as the revenue we expect to receive from our customers over the course of the following year for providing them with products or services.
- ARR includes expected revenue from all customers who are using our products or services at the reported date.
- However, we believe that over time these significant challenges facing pharmacists will drive demand for increased automation, visibility, insights, and improved medication management outcomes that our solutions are designed to enable.
- As a market leader, we anticipate continued expansion into this product market as customers increasingly utilize our dispensing systems in more areas within hospitals and ambulatory care settings.
Omnicell's latest quarter
Omnicell, Q3 2026: revenue $308M (-0.9% year over year), operating margin 4.9%, net earnings $11.0M, operating cash flow $33.1M. The chart follows the revenue to costs, profit and cash.
Questions
Did Omnicell raise or lower its guidance?
Omnicell (OMCL) raised some and lowered other parts of its guidance on Oct 29, 2026: Revenue $295M–$301M for Q4 2026; Revenue $1.2B for FY2026.
What does Omnicell expect?
• our ability to successfully achieve anticipated growth targets or market adoption; • failing to maintain expected service levels when providing our SaaS and Expert Services or retaining our SaaS and Expert Services customers; • failing to meet (or significantly exceeding) our publicly announced financial guidance; and
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.